The Urine Albumin Creatinine Ratio (UACR) is an important indicator of kidney health that is used by doctors to assess the risk of developing chronic kidney disease (CKD). UACR is a measure of the amount of albumin, a protein, that is present in the urine, relative to the amount of creatinine, a waste product formed in the body. UACR is a useful tool for doctors to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease.
UACR is a simple test that measures the amount of albumin and creatinine in a person's urine. Albumin is a protein that is normally found in the blood, but can be found in higher concentrations in the urine when the kidneys are not functioning properly. Creatinine is a waste product formed in the body and is normally excreted through the urine. UACR is measured by dividing the amount of albumin present in the urine (measured in milligrams per gram of creatinine) by the amount of creatinine present in the urine (measured in milligrams per gram of creatinine). The result is expressed as a ratio.
UACR is used to detect early signs of kidney damage, as well as to monitor the progression of CKD. UACR can be used to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease. UACR can also be used to assess the effectiveness of treatments, such as medications or lifestyle changes, that are used to slow the progression of CKD. UACR is also used to monitor patients who have already been diagnosed with CKD to ensure that their kidney function is not deteriorating further.
The normal range for UACR is 0-30 mg/g. A UACR of 30 mg/g or higher is considered abnormal and may indicate the presence of kidney disease. It is important to note that a UACR of 30 mg/g or higher does not necessarily mean that a person has CKD. UACR can be elevated due to other factors, such as dehydration, infection, or certain medications. Therefore, it is important to consult with a doctor to determine the cause of an elevated UACR.
UACR testing is recommended for anyone who is at risk for developing CKD, including those with diabetes, hypertension, or a family history of CKD. Additionally, UACR testing is recommended for anyone who is already diagnosed with CKD, to monitor for any changes in kidney function.
The Urine Albumin Creatinine Ratio (UACR) is an important indicator of kidney health that is used by doctors to assess the risk of developing chronic kidney disease (CKD). UACR is a measure of the amount of albumin, a protein, that is present in the urine, relative to the amount of creatinine, a waste product formed in the body. UACR is a useful tool for doctors to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease. UACR testing is recommended for anyone who is at risk for developing CKD, including those with diabetes, hypertension, or a family history of CKD. Additionally, UACR testing is recommended for anyone who is already diagnosed with CKD, to monitor for any changes in kidney function.
1.
Certain surgical gestures during prostate removal linked to better sexual function recovery
2.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
3.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
4.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
5.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
1.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
2.
Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After
3.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
4.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
5.
ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation